CYP3A4 and cancer: Association of TKIs and DOACs is common in cancer patients, to prevent venous thromboembolism, but TKIs’ influence upon P-gp and CYP3A4 affects DOAC (dabigatran, apixaban, rivaroxaban, edoxaban) plasmatic concentrations.